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Abstract: 
Goals 
The aims of this secondary data analysis were to (a) categorize patterns in the development, 
duration, intensity, and resolution of sore mouth (which can be considered a proxy for oral 
mucositis) severity and distress over two cycles of chemotherapy in cancer outpatients and (b) 
examine the relationship of demographic (age, gender, marital status, and educational level) and 
disease characteristics (type of cancer and type of chemotherapy) to specific patterns of sore 
mouth (SM). 
Materials and methods 
Visual graphical analysis (VGA) was applied to identify individual patterns of SM severity and 
distress in 51 outpatients receiving chemotherapy who provided daily reports of sore mouth 
using a computerized interactive voice response system. The majority were female (n = 41, 8%) 
with a mean age of 53 (SD = 8.35). Most had breast cancer (68%), and one third received 
chemotherapy with adriamycin and cyclophosphamide (AC). VGA is a technique in which 
graphs of individual patients’ symptoms are coded for specific individual or group profiles. 
Main results 
Seven distinct patterns were identified based on variability in onset, duration, and intensity 
(degree of severity or distress). Chemotherapy agents were significantly associated with patterns 
of SM. The AC regimen was significantly associated with late onset; however, the intensity did 
not last long. In contrast, patients receiving R-CHOP were significantly more likely to 
experience duration intensity (SM after day 15 and a score equal to or greater than a 5 on a 1–10 
scale). 
Conclusions 
VGA revealed symptom patterns often hidden in traditional analysis. Understanding individual 
variability is important to the design and implementation of future intervention research and 
clinical care. 
oral mucositis | chemotherapy | outpatient cancer treatments | cancer patients | cancer Keywords: 
outpatients | health sciences 
Article:  
Introduction 
 
While contemporary cancer therapies can be highly effective in curing or stabilizing the cancer 
patient, debilitating side effects, such as oral mucositis (OM), continue to compromise delivery 
of optimal therapeutic regimens. In addition, the toxicities from cancer treatment can affect 
overall quality of life [12, 15]. Almost 90% of the one million cancer patients treated with 
chemotherapy in the USA receive these medications on an outpatient basis; thus, OM can be a 
frequently encountered toxicity in clinical oncology practice [11]. Once patients leave the clinic 
or physician office, assessment is challenging; thus, OM often goes unreported and untreated. 
In spite of an increase in research on OM [13], there are still important gaps in our knowledge 
for at least three fundamental reasons. First, most longitudinal research of OM has been 
conducted with inpatients receiving high-dose chemotherapy for blood and marrow stem cell 
transplantation [6, 7, 18] or with patients receiving radiation therapy [20]. Few studies have 
included outpatients receiving chemotherapy as participants; thus, little is known about the 
trajectories and patterns of OM in this population. In one intervention study, Dodd et al. [4] 
investigated the incidence of chemotherapy-induced OM in outpatients over 3 months; however, 
daily assessments were not completed and results were reported in aggregate. 
Second, only a minimal amount of research has been conducted that examines OM longitudinally 
over an entire course of chemotherapy regardless of whether chemotherapy was administered on 
either an outpatient or inpatient basis. In addition, few studies have investigated OM over 
consecutive cycles of outpatient chemotherapy. 
Third, most research studies have used standard analytic approaches with summary statistics to 
explore changes in OM over time; such approaches may mask some of the clinical variability 
seen in practice. Several important descriptive and intervention studies have included daily 
measures of OM using a variety of measures. All of theses studies reported change over time 
using group level summary statistics such as means and standard deviations at each time point [6, 
7, 17, 18]. These studies, all conducted in hematopoietic stem cell transplant settings, revealed 
group level patterns in which OM peaked after myeloablative therapy and then gradually 
recovered as the bone marrow rebounded. However, the use of traditional statistical methods to 
summarize group change over time may have obscured individual trajectories of change [1]. 
The incidence of OM depends on the particular antineoplastic treatment regimens and patient-
specific characteristics. Anthracycline-based regimens are associated with rates of OM around 1–
10%, including those standard regimens for adjuvant treatment in patients with breast cancer 
(doxorubicin and cyclophosphamide) and regimens for non-Hodgkin’s lymphomas 
(cyclophosphamide, doxorubicin, vincristine, and prednisone) [16]. Further, there is an increased 
risk of OM when rituximab is added to the above regimens when used in the treatment of breast 
cancer [16]. When 5-FU (commonly used in colon and some breast cancer regimens) is 
administered, the rates of grades 3 and 4 OM are greater than 15% [16]. There is no research to 
explore whether patterns of OM over time are associated with type of regimen. 
There is some limited evidence that gender and age may be risk factors for OM. Vokurka et al. 
[19] reported a higher incidence of chemotherapy-induced OM in females when compared with 
males. Raber-Durlacher et al. [10] suggested that patients over 50 years of age develop OM that 
is more severe and has a longer duration. They proposed that this more intense and prolonged 
OM might be related to a decline in renal function in patients over 50. 
The clinical literature has always consistently suggested a typical pattern of OM in patients 
receiving chemotherapy. Erythema is typically the earliest clinical sign of OM, occurring 
approximately 4–5 days following chemotherapy administration [12]. Ulcers then develop 7–10 
days following chemotherapy, creating marked discomfort for patients, many of whom require 
opioid medications for pain relief. OM resulting from chemotherapy administration typically 
lasts 1 week and usually heals within 21 days after administration [12]. Despite these typical 
characteristics, few studies examine variation in these trajectories within a given cancer patient 
cohort, particularly in an outpatient setting. 
In summary, there are important limitations to existing research, which include a primary focus 
on inpatient, high-dose chemotherapy populations, the use of traditional statistical analyses that 
can sometimes obscure individual trajectories of OM, and a limited number of longitudinal 
studies investigating OM over more than one cycle of chemotherapy. One key reason for these 
limitations is the impracticality and cost associated with observational studies of OM when 
outpatients receive their chemotherapy and return to their home setting. This report takes 
advantage of an innovative approach to studying symptoms on a daily basis using computerized 
interactive voice technology. We have specifically focused on daily self-reports of sore mouth 
(SM) severity and distress, a reasonable proxy for OM used by other researchers [6, 7] that is 
easy for patients to understand and report. 
Thus, the aims of this secondary data analysis were to (a) explore and categorize patterns in the 
development, duration, intensity, and resolution of SM severity and distress over two cycles of 
chemotherapy in cancer outpatients and (b) describe and explore the relationship of demographic 
(age, gender, marital status, and educational level) and disease characteristics (type of cancer and 
type of chemotherapy) to specific patterns of SM. 
Materials and methods 
 
Parent study 
 
A secondary data analysis was performed using visual graphic analysis to investigate individual 
patterns of SM severity [1]. The analysis was based on data from a multi-site, prospective 
randomized clinical trial of patients receiving outpatient chemotherapy [8] (NCI R01 CA89474). 
The purpose of the parent study was to assess the efficacy of telephone-linked care for 
chemotherapy alerting (TLC-Chemo Alert) in the symptom management of adults receiving 
chemotherapy for cancer. A total of 223 patients participated in this study. 
TLC chemotherapy alerting mechanism was a computer-based communication system that used 
interactive voice technology to gather and to electronically document cancer patients’ daily 
symptom experience by means of automated telephone conversations. The TLC-Chemo alert 
technology is a well-validated technology that included standardized patient response formatting. 
The inclusion and exclusion criteria for the parent study sample are summarized in Table 1. 
Patients were screened at the end of cycle 1 to confirm that they experienced a symptom that was 
at least moderate in intensity during their first cycle. Eligible patients who provided informed 
consent then provided daily data via the TLC system for cycles 2 and 3. 
Table 1 
Inclusion and exclusion criteria of parent study 
Inclusion criteria 
Adult (age 18 or over) 
Histologic diagnosis of cancer 
A life expectancy of at least 6 months 
Cognitively able to participate (as verified by the provider team) 
At the end of their first cycle of a new course of chemotherapy that was planned for a minimum 
of 3 cycles 
Poorly controlled symptoms during the first cycle of the chemotherapy (based on a phone 
screening) 
Exclusion criteria 
Receiving concurrent radiation therapy 
Biotherapy only 
Initial demographic and clinical variables were collected from participants at the beginning of 
the study. Patients were instructed to call into TLC each day during cycles 2 and 3 of 
chemotherapy and to answer a series of questions that focused on the presence/absence of nine 
symptoms associated with chemotherapy, including SM. Single-item indicators using a 
standardized approach for each symptom were utilized—such measures are generally used to 
obtain the subject’s perception of particular dimensions of multidimensional concepts or of an 
overall concept. Because data collection was daily, it was essential to keep the response burden 
to a minimum. Youngblut and Casper [21] reviewed numerous clinical studies that used single-
item indicators including items to measure symptom severity, concluding that there was evidence 
to support the reliability and validity of single-item indicators. This approach is also commonly 
applied in numerous multi-symptom inventories including the Memorial Symptom Assessment 
Scale and the MD Anderson Brief Symptom Inventory [2, 3]. 
A hallmark symptom of OM is acute pain of the affected oral mucosa; thus, patients often 
describe OM as a SM. Use of this term allowed patients to report sore mouth via a pre-recorded 
script. If patients indicated they had a SM, they were asked specific standardized questions about 
their SM experience, including how they would rate their level of SM severity and distress on a 
scale of 1 (minimal) to 10 (worst). A distinct advantage of the dataset is that it provided daily 
data on the symptom experience through two cycles of chemotherapy. 
Visual graphic analysis 
 
Visual graphic analysis (VGA) is a technique in which individual patients’ symptoms are 
graphed and inspected for patterns over time [1]. VGA provides researchers with an alternative 
method to quantitative statistical analysis, as it enables careful inspection of individual variations 
and patterns of change that can be obscured by traditional parametric statistics. A goal of VGA is 
to disclose common patterns and to pinpoint individuals whose data do not conform to common 
trajectories. Of particular interest were questions such as when does a SM first occur, how severe 
does it become, and how long does it last? These questions were best addressed by VGA. The 
VGA analysis was performed in five steps as described in detail by Brown et al. [1] and 
summarized below. 
Step 1: 
Determining inclusion criteria. The study had two inclusion criteria. First, only those patients 
who reported three or more episodes of a SM during cycle 2 or cycle 3 of their respective 
chemotherapy treatments were included. At least three data points are needed for pattern 
analysis, and reports of sore mouth for more than one or two times would be most consistent 
with oral mucositis. Second, chemotherapy treatment was limited to the first 21 days of data 
within each cycle, thus assuring that all graphical plots were based on the same abscissa. For 
purposes of this study, a cycle was defined as a 21-day period in which chemotherapy was 
administered on day 1 and not again for another 20 days. 
  
Step 2: 
Managing missing data. “No call” missing data occurred when participants never called into the 
TLC system or terminated a call. These episodes were categorized as missing data and were 
displayed on the graph as gaps in the plots. Of the 1,554 days available (74 graphs × 21 days), 
225 days were missing (14.5%). 
  
Step 3: 
Creating individual visual graphs. Data from each episode of SM severity were charted on 
individual graphs using Microsoft Excel. Identical axes were used for each respective participant 
or symptom being plotted. This methodology prevented the visual distortion of scales that can 
occur with many software packages which automatically expand or contract scales to complete a 
page or plot area [14]. 
  
Step 4: 
Identifying specific individual patterns. All graphs were examined to discover any 
commonalities and differences in the 21-day trajectories of a SM. The word intensity was used to 
refer to the degree of severity or distress reported. Seven patterns were identified: early Onset 
(between days 1 and 5); middle onset (between days 6 and 9); late onset (beginning on or after 
day 10); onset intensity (first response greater than a 5 on 1–10 scale); duration intensity (after 
day 15 and a SM score equal to or greater than a 5 on a 1–10 scale); late duration (continuing 
after day 15); and low intensity (no response greater than 4 on a 1–10 scale). Once the patterns 
were determined, the individual graphs were visually sorted into these seven pattern groups and 
labeled. It was possible for any single graph to be categorized into more than one pattern group. 
  
Step 5: 
Performing validation and verification. Members of the research team reviewed and 
independently verified coding of each graph. When differences occurred, they were discussed 
until a consensus was reached. 
  
Data analysis 
 
Data analysis was performed using SPSS (version 11). Multiple analyses using cross-tabulations 
with chi-square tests were conducted to evaluate whether any differences in demographic or 
clinical characteristics existed among individuals categorized into each of the seven pattern 
groups. We collapsed categories to improve the power of the chi-square analyses as appropriate 
and meaningful, and cell sizes were adequate for the total number of cells included (i.e., at least 
five per cell). However, in some instances (e.g., type of chemotherapy), inclusion of specific 
categories was most meaningful even if there were less than five cases in some cells. We 
recognized that findings are not definitive but may inform future studies 
The three onset patterns were combined into a new variable called onset that consisted of three 
levels (early, middle, and late onset). The other pattern variables (onset intensity, duration 
intensity, late duration, and low intensity) consisted of two levels, either “yes” (for those 
assigned to the pattern) or “no” (for those not assigned to the pattern). Demographic variables 
were collapsed in order to have adequate cell sizes to conduct chi-square tests as follows: gender 
(male or female), marital status (married or non-married), educational level (high school or 
college), and income level (0–39,999or40,000 and above). Treatment variables included type of 
cancer (breast, non-Hodgkin’s lymphoma, or other cancers) and type of chemotherapy 
[doxorubicin and cyclophosphamide (AC); cyclophosphamide, methotrexate, and flurouracil 
(CMF); rituximab plus cyclophosphamide, oncovin, doxirubicin, and prednisone (R-CHOP); and 
other chemotherapies]. An independent-samples t test was conducted to evaluate whether there 
was a difference in age between those who were and who were not assigned to a certain onset 
pattern group. Since the variable of onset had three levels (early, middle, and late), analysis of 
variance (ANOVA) was used to determine differences in age. 
Results 
 
Of the 223 study participants, 115 (51%) reported SM at any point in time. Of the 115 patients 
reporting SM, 51 participants reported three or more days of SM in either the second (n = 45) or 
third (n = 29) cycle of chemotherapy, yielding74 graphs for analysis. The demographic and 
clinical characteristics of participants with SM are presented in Table 2. The majority of the 
participants were female (n = 41, 82%) with a mean age of 53 years (SD = 8.35). Most were 
married (68%), with a diagnosis of breast cancer (68%), and receiving chemotherapy of AC 
(33.3%). Approximately 30% of the participants had some college or trade school education, and 
approximately 40% reported earning more than $70,000 per year. 
Table 2 
Characteristics of participants reporting SM (n = 51) 
Variables M SD n Percentage 
Age 53.36 8.35     
Gender 
Male     9 17.6 
Female     41 82.0 
Missing     1 – 
Marital status 
Single     5 10.6 
Married     32 68.1 
Divorced/widowed     10 21.3 
Missing     4 – 
Educational level 
High school graduate     9 19.1 
Some college     14 29.8 
Associates degree     6 12.8 
Variables M SD n Percentage 
Bachelor’s degree     8 17.0 
Postgraduate     10 21.3 
Missing     4 – 
Income         
$0–19,000     4 10.0 
$20,000–49,000     13 32.5 
$50,000–69,000     7 17.5 
Above $70,000     16 40.0 
Missing/refused     11 – 
Cancer 
Breast     32 62.7 
NHL     5 9.8 
Other     10 19.6 
Missing     4 – 
Chemotherapy 
AC     16 33.3 
CMF     6 12.5 
Taxol/other     8 16.7 
Variables M SD n Percentage 
RCHOP     4 8.3 
Other     14 29.2 
Missing     3 – 
 
Aim 1 was to explore and categorize patterns in the development, duration, intensity, and 
resolution of SM severity and distress over two cycles of chemotherapy in cancer outpatients. By 
using VGA, plots were categorized into the seven patterns mentioned earlier: early onset (n = 17; 
see Fig. 1); middle onset (n = 43; see Fig. 2); late onset (n = 14; see Fig. 3); onset intensity (n = 6; 
Fig. 4); duration intensity (n = 13; see Fig. 5); late duration (n = 19; see Fig. 6); and low intensity 
(n = 36; see Fig. 7). As noted previously, every participant was sorted into one of the levels of 
onset (early, middle, and late) and then into any of the other pattern groups that appeared to 
apply to the data (onset intensity, duration intensity, late duration, or low intensity). 
Figures 1-7 are omitted from this formatted document. 
A small group of patients (n = 14) presented a pattern of two episodes of SM severity occurring 
during one cycle of chemotherapy separated by at least 2 days of no SM (see Fig. 8). Because 
some of the patients reported SM at the onset of a cycle and then again at least 2 days later in the 
cycle, dates at the end of cycle 2 and the beginning of cycle 3 were verified to ensure that the 
two episodes were indeed in the same cycle. 
Figure 8 is omitted from this formatted document. 
VGA analysis of SM distress revealed that in virtually every case, SM distress scores were very 
similar to those for SM severity (see Fig. 9). Equivalence was verified by computing a daily 
difference score between severity and distress. Interestingly, of the 1,007 daily difference scores, 
97% of the severity and distress scores differed by one or less. Thus, patterns of distress and 
severity were judged as equivalent. 
Figure 9 is omitted from this formatted document. 
Aim 2 was to describe and explore the relationship of demographic (age, gender, marital status, 
and educational level) and disease characteristics (type of cancer and type of chemotherapy) to 
specific SM patterns. Table 3 presents the statistical results (χ 2 and t) and the significance of 
relationships between participants’ characteristics and patterns of SM. Similar to the patients 
who reported SM, those patients who did not report SM were mostly female (78%) with a mean 
age of 57.8 years (SD = 12.18). The majority of them were Caucasian (92%), married (75%), 
with a diagnosis of breast cancer (33%), and received AC as treatment. 
Table 3 
Statistical results (χ 2 and t) and significance of relationships between participant characteristics 
and patterns of SM (n = 74) 
Variables χ 2 p T p value 
Onset (early, middle, late) 
Marital status 7.08 0.03 – – 
Gender 2.14 0.34 – – 
Income 4.48 0.28 – – 
Educational level 6.11 0.05 – – 
Cancer 9.03 0.06 – – 
Chemotherapy 24.86 0.00 – – 
Onset intensity 
Age – – −1.65 0.11 
Marital status 1.31 0.29 – – 
Gender 1.28 0.26 – – 
Income 3.01 0.08 – – 
Educational level 0.80 0.37 – – 
Cancer 9.48 0.01 – – 
Variables χ 2 p T p value 
Chemotherapy 16.00 0.00 – – 
Duration intensity 
Age – – −0.85 0.40 
Marital status 0.45 0.50 – – 
Gender 1.87 0.17 – – 
Income 0.06 0.81 – – 
Educational level 0.00 0.97 – – 
Cancer 9.10 0.01 – – 
Chemotherapy 12.27 0.02 – – 
Late duration 
Age – – −0.75 0.46 
Marital status 0.16 0.69 – – 
Gender 1.95 0.16 – – 
Income 0.07 0.79 – – 
Educational level 0.00 0.97 – – 
Cancer 6.42 0.04 – – 
Chemotherapy 7.89 0.10 – – 
Low intensity 
Variables χ 2 p T p value 
Age – – −0.54 0.59 
Marital status 1.43 0.23 – – 
Gender 3.55 0.06 – – 
Income 0.52 0.47 – – 
Educational level 0.39 0.53 – – 
Cancer 7.57 0.02 – – 
Chemotherapy 6.84 0.15 – – 
 
Onset 
 
Table 4 presents the relationship between the significant variables (marital status and 
chemotherapy type) and the pattern of onset of SM. There was a significant association between 
marital status coded as married versus not married [single, divorced, or widowed; χ 2(2) = 7.08, 
p = 0.03]. The strength of the relationship between married and non-married was low (Φ = 0.32), 
although the nature of the association as indicated by adjusted residuals [9] suggested that non-
married individuals tended to show early onset more often than married individuals. The results 
of the chi-square analysis indicated a statistically significant but weak association between those 
in the early, medium, and late onset and the chemotherapy type they received [χ 2(4) = 24.86, 
p = 0.002, Cramer’s V = 0.42]. An examination of standardized residuals [9] suggested that 
patients who received AC (3.7) were more likely to experience late onset SM. Patients who 
received CMF (2.6) experienced middle onset, and patients who received some of the “other” 
drugs (2.6) were more likely to experience early onset. There were no significant differences 
between these three groups (early, middle, and late onset) in gender, educational level, and type 
of cancer. Further, an ANOVA showed there was no significant difference in age 
[F(2,67) = 2.43, p = 0.10] between the three levels of onset. 
 
Table 4 
Percentages and adjusted residuals of marital status and chemotherapy type and pattern of onset 
of SM 
  
Marital status Chemotherapy 
Not 
married Married AC CMF Taxol/other RCHOP Other 
Early 
N 10 7 4 0 2 1 10 
Percentage 43.5 15.2 17.4 0.0 20.0 16.7 43.5 
Adjusted 
residual 2.6a −2.6a −0.9 −1.7 −0.3 −0.5 2.6a 
Middle 
N 11 29 9 8 7 3 13 
Percentage 47.8 63.0 39.1 100.0 70.0 50.0 56.5 
Adjusted 
residual −1.2 1.2 −2.1a 2.6a 0.9 −0.4 −0.1 
Late 
N 2 10 10 0 1 2 0 
Percentage 8.7 21.7 43.5 0.0 10.0 33.3 0.0 
Adjusted 
residual −1.3 1.3 3.7a −1.4 −0.8 1 −2.8a 
aSignificant adjusted residuals > the absolute value of 2 
Onset intensity 
Table 5 summarizes the relationships among cancer type, chemotherapy administered, and 
patterns of SM for onset intensity, duration intensity, late duration, and low intensity. There were 
no significant differences between those in the onset intensity group and those who were not in 
the group on marital status, gender, age, income, or educational level. However, a chi-square 
analysis revealed a statistically significant but weak association between those patients in the 
onset intensity group and those not in it in terms of cancer diagnosis [χ 2(2) = 9.48, p = 0.009, 
Cramer’s V = 0.37]. An examination of standardized residuals suggested that patients with non-
Hodgkin’s lymphoma (NHL, −3.1) were significantly less likely to be sorted into the onset  
intensity group. There was a significant association in these two onset intensity groups in terms of the chemotherapy they received 
[χ 2(2) = 16.00, p = 0.003, Cramer’s V = 0.48]. Those receiving R-CHOP seem to have a different pattern and may be more likely to 
have onset intensity than women with breast cancer. None of these R-CHOP patients were in the low intensity group. These results 
must be viewed as tentative because of the number of cells with less than five, which violates the assumption of the analysis. 
Table 5 
Percentages and adjusted residuals for cancer type and chemotherapy administered and patterns of SM 
  Onset intensity Duration intensity Late duration Low intensity 
 
No, 
n(%) 
Yes, 
n(%) 
Residuala No, 
n(%) 
Yes, 
n(%) 
Residuala No, 
n(%) 
Yes, 
n(%) 
Residuala No, 
n(%) 
Yes, 
n(%) 
Residuala 
Cancer type 
Breast 
42 
(66.7) 
2 
(33.3) 1.6 
35 
(62.5) 
9 
(69.2) 0.5 
30 
(60.0) 
14 
(73.7) 1.1 
25 
(71.4) 
19 
(55.9) 1.3 
NHL 5 (7.9) 
3 
(50.0) 3.1b 4 (7.1) 
4 
(30.8) 2.4b 4 (8.0) 
4 
(21.1) 1.5 6 (17.1) 2 (5.9) 1.5 
Other 
16 
(25.4) 
1 
(16.7) 0.5 
17 
(30.4) 0 (0) 2.3b 
16 
(32.0) 1 (5.3) 2.3b 4 (11.4) 
13 
(38.2) 2.6b 
Chemotherapy 
AC 
23 
(35.9) 0 (0) 1.8 
18 
(31.6) 
5 
(38.5) 0.5 
16 
(31.4) 
7 
(36.8) 0.4 
11 
(31.4) 
12 
(34.3) 0.3 
  Onset intensity Duration intensity Late duration Low intensity 
 
No, 
n(%) 
Yes, 
n(%) Residual
a 
No, 
n(%) 
Yes, 
n(%) Residual
a 
No, 
n(%) 
Yes, 
n(%) Residual
a 
No, 
n(%) 
Yes, 
n(%) Residual
a 
CMF 
7 
(10.9) 
1 
(16.7) 0.4 
7 
(12.3) 1 (7.7) 0.5 5 (9.8) 
3 
(15.8) 0.7 4 (11.4) 4 (11.4) 0 
Taxol/oth
er 
9 
(14.1) 
1 
(16.7) 0.2 
10 
(17.5) 0 (0) 1.6 
9 
(17.6) 1 (5.3) 1 4 (11.4) 6 (17.1) 0.7 
RCHOP 3 (4.7) 3 (50) 3.8b 2 (3.5) 
4 
(30.8) 3.2b 2 (3.9) 
4 
(21.1) 2.3b 
16 
(17.1) 0 (0) 2.6b 
Other 
22 
(34.4) 
1 
(16.7) 0.9 
20 
(35.1) 
3 
(23.1) 0.8 
19 
(37.7) 
4 
(21.1) 1.3 
10 
(28.6) 
13 
(37.1) 0.8 
 
aResidual presented as absolute value 
bSignificant adjusted residuals >2 
 
 
 
 
 
Duration intensity 
There were no significant differences between those in the duration intensity group and those 
who were not on gender, age, marital status, educational level, or income level. There were 
statistically significant yet weak differences between these two groups in terms of cancer 
diagnosis [χ 2(2) = 9.10, p = 0.011, Cramer’s V = 0.36] and chemotherapy 
[χ 2(4) = 12.27, p = 0.015, Cramer’s V = 0.41]. Interestingly, patients with “other” cancers were 
never sorted into the group that experienced duration intensity. Patients who received R-CHOP 
(3.2) were significantly more likely to experience duration intensity, but not those patients who 
received AC (0.5). 
Late duration 
There were no significant differences between those in the late duration group and those who 
were not on gender, age, marital status, educational level, income level, and type of 
chemotherapy administered. There was a statistically significant yet weak association between 
the late duration and the non-late-duration groups on the type of cancer diagnosis 
[χ 2(2) = 6.42, p = 0.040, Cramer’s V = 0.30]. Adjusted residuals showed that those patients in the 
“other” cancer group (2.3) were significantly less likely to experience late duration. In fact, only 
one patient who experienced late duration had an “other” cancer diagnosis. 
Low intensity 
Chi-square analysis revealed a statistically significant yet weak association between those 
patients in the low intensity group and those not in it in terms of cancer diagnosis 
[χ 2(2) = 7.57, p = 0.023, Cramer’s V = 0.33]. Examination of standardized residuals suggested 
that patients who were in the “other” cancer diagnosis group (2.6) were significantly more likely 
to experience low intensity SM. There were no significant differences between those in the low 
intensity group and those not in it on gender, age, marital status, educational level, income level, 
and type of chemotherapy administered. 
In summary, there were statistically significant differences between the three onset groups by 
marital status, as non-married patients were more likely to report onset earlier than married 
patients. Concerning the type of cancer, patients with “other” cancers tended to experience a SM 
with lower intensity and without duration intensity and/or late duration. Patients with NHL did 
not experience a SM associated with onset intensity. Concerning the type of chemotherapy 
administered and patterns of a SM, the following associations between type of chemotherapy and 
SM patterns were noted: 
• AC was significantly associated with late onset, but not duration intensity. 
• R-CHOP was significantly associated with duration intensity. 
• CMF was significantly associated with middle onset. 
• “Other” chemotherapy drugs (fluorouracil, cisplatin) were associated with early onset. 
 
Sore mouth longitudinal daily mean scores 
 
Although mean scores may hide the individual patterns of sore mouth, these data are presented in 
Fig. 10. Very few studies have presented daily sore mouth severity scores in outpatient 
populations receiving chemotherapy. 
Figure 10 is omitted from this formatted document. 
Discussion 
 
Results from this study demonstrated that cancer patients receiving outpatient chemotherapy 
experience several different patterns of SM severity and distress. A majority of patients (n = 43) 
experienced middle onset SM occurring sometime between days 6 and 9. This middle onset 
pattern is commonly witnessed in clinical practice, yet is later than the days 4 to 5 onset that is 
suggested in the clinical literature. Moreover, middle onset was not the only onset pattern. Some 
patients reported the early onset of SM within 1–3 days after receiving chemotherapy treatment. 
Other patients reported a late onset of SM in which the first incidence of SM was not reported 
until day 10 or later. These findings of early and late onset challenge the usual clinical 
assumption and observations that most acute mucosal injuries induced by chemotherapy develop 
within 1 week of drug administration (usually by day 4 or 5) and peaks within 2 weeks [15]. It is 
likely that these two patterns of onset would have been missed if intermittent measurements 
common in clinical practice (such as the beginning of chemotherapy and maybe the nadir) and 
traditional summary statistics were used to conduct the data analysis. 
In the next pattern, onset intensity, patients reported their first complaint of a SM as above a 
score of 5 on a 1–10 scale. This new and unique finding suggests that for some patients, there is 
not a gradual increase in SM discomfort over a few days. Instead, SM begins in the moderate 
range without a slow period of development. This pattern is of particular concern because it may 
be more difficult to assist patients with pain control when SM is moderate to severe at its first 
appearance. All graphs sorted into the onset intensity category were evaluated to confirm that the 
days prior to the first response were not missing days (see Fig. 4); in all instances, the days prior 
were true SM severity ratings of zero as opposed to missing data. 
Approximately half of the patients were coded into the low intensity pattern, defined as a 
severity response never exceeding 4 on a 1–10 scale. This pattern, along with middle onset, are 
perhaps two of the most common patterns of SM seen in clinical practice, especially in patients 
receiving outpatient chemotherapy. Two other patterns included late duration and duration 
intensity. Approximately one fourth of patients (26%) demonstrated a SM severity response that 
persisted after day 15 of treatment and was an example of late duration. Other patients (18%) 
reported a SM after day 15 and rated the SM as being 5 or greater (duration intensity), suggesting 
that some patients experience a SM lasting well after day 15 and at an intensity higher than 5 on 
a 1–10 scale. These patients may require more intensive pain intervention. 
In addition, during the process of visual graphing, the first author discovered a new pattern of 
two episodes of SM separated by at least 2 days of no SM (see Fig. 9). This finding represents a 
unique dynamic that has not been previously described in the literature. Further research using 
prospective designs is needed to verify if participants actually experience a few days of SM, 
followed by a few days of no report of a SM, followed by more days of SM. It would be helpful 
in this instance to use actual measures of OM instead of self-reported SM. If research supports 
the presence of more than one episode of SM during a cycle, it would be interesting to 
investigate the correlation of these episodes with potential clinical risk factors such as patient’s 
nadir, infection, renal function, or dehydration. For instance, when a patient experiences two 
episodes of SM, are those episodes in congruence with the beginning and end of neutropenia or 
with some other physiologic event? The detection of this unusual pattern would likely have been 
missed using traditional statistics, thus highlighting the advantages of VGA. 
As previously noted, patients in this study had already received one cycle of chemotherapy prior 
to study entry. Patients had experienced at least one symptom of moderate intensity in order to 
be included in the study. Some of the participants during cycle 1 also experienced selected 
associated symptoms such as nausea, difficulty sleeping, and SM. Therefore, patients may have 
be more acutely aware of a particular symptom, leading them to report symptoms that occurred 
earlier and/or later and at a higher intensity following chemotherapy. Additionally, VGA may 
have helped identify a subset of patients who experienced SM differently than previously 
understood. By investigating patterns of a symptom individually over time, a new understanding 
of those patterns is presented. 
Findings from this secondary analysis suggest that there are levels of variability in patients’ 
patterns of SM. No two patients presented with SM (or other symptoms) in exactly the same 
manner. These findings challenge health care providers and researchers to think differently about 
patients experiencing SM because not all patients are alike. Thus, assessment and management 
procedures need more individualization than previously thought. It is imperative for clinicians 
and researchers to continue vigilant assessment of SM across the entire treatment period. The 
timing of assessment is important in studies focusing on SM, since studies that only measure the 
symptom at day 5 or on a weekly basis might miss important data. Thus, oral assessment should 
occur more frequently, for longer periods of time after treatment, and on a more consistent, daily 
schedule. Even self-reports can clue the clinician to the need for a more thorough oral exam for 
full diagnosis and intervention. 
Assessment is a particularly challenging endeavor for outpatients because of their non-
availability in between treatments. Clinicians and researchers must think of other innovative 
techniques to assess outpatients. Assessment tools such as TLC alert or daily questionnaires such 
as those used by Stiff et al. [18] or Wong et al. [20] that gather information from patients at 
home might be an answer to meeting this challenge. Another option is to teach patients to do a 
simple visual inspection of their oral cavity using a simple OM assessment tool and reporting 
changes in color, ulcerations, etc. It is also important for researchers to report patients’ adherence 
rates to conducting such exams and reporting the results when these daily questionnaires are used 
by patients to help determine the feasibility of using the questionnaires in research. 
In addition, it is beneficial to assess patterns of SM longitudinally over two or more cycles of 
chemotherapy to get a more accurate picture of any given patient’s trajectory. Since clinical 
factors such as chemotherapy regimens and type of cancer seem more important in relation to 
patterns of SM, increased focus on surveillance and assessment should be included when patients 
are treated with antineoplastic agents that have been shown in the literature to cause more severe 
or unusual patterns of SM [5]. 
Finally, assessment should include particular patient characteristics such as age, marital status, 
and educational level. Recall that non-married patients were more likely to report early onset of 
SM. Further research is needed, but it may be that those patients who receive emotional and 
physical support report SM later and at a lower severity. Thus, there is a need to include 
particular patient characteristics in clinical assessment and research. 
This study demonstrated significant relationships between particular chemotherapy agents and 
patterns of OM. Amongst participants from this study, the AC regimen was significantly 
associated with late onset; however, the duration of the onset was not particularly intense. Quite 
the opposite, patients receiving RCHOP were significantly more likely to experience duration 
intensity. Interestingly, both regimens contain doxorubicin and cyclophosphamide, yet only 
those patients receiving R-CHOP got rituximab. Perhaps, rituximab was responsible for the 
longer duration and intensity of SM. In an extensive study of OM, Sonis et al. [16] noted that 
grades 3 and 4 OM were seen in approximately 10% of patients receiving a combination of 
doxorubicin and cyclophosphamide. The regimen CMF was significantly associated with middle 
onset, while “other” chemotherapy drugs (flurouracil, cisplatin) tended to cause early onset SM. 
Future studies should investigate duration, onset, incidence, and intensity of SM in particular 
chemotherapies. In studies with heterogeneous treatment regimens, it is important to analyze 
patterns related to treatment. 
Another interesting finding was that 97% of participants ranked their daily severity and distress 
scores within one point or less of each other. There may be at least two reasons why participants 
rated severity and distress similarly. First, patients may really have felt that severity and distress 
were very similar. Second, patients may not have understood the conceptual differences between 
the meaning of the words “severity” and “distress” and may, thus, have viewed them as the same 
thing. In future studies, it may be helpful to carefully define the words severity and distress to 
patients so that they can understand what is being asked. 
Limitations 
 
This study was limited by several issues. First, the findings from the study are not generalizable 
beyond the study sample, which consisted primarily of married Caucasian women with some 
college education and with a diagnosis of breast cancer. Future research should include increased 
participation by minorities, men, people from other socioeconomic backgrounds, and people with 
other cancer diagnoses. We also exclude participants who only reported a sore mouth once or 
twice; some of these patients may have had OM. 
Another limitation was the number of cycles each participant received. All participants received 
one cycle of chemotherapy before beginning the TLC study; recall data from this cycle were 
used to determine eligibility. Thus, those who had early onset of SM may have been displaying 
sustained responses related to their prior experience of a SM in cycle 1 of chemotherapy. 
Further, it is not known what other clinical interventions occurred during the first cycle of 
chemotherapy. For instance, a participant who had more intense SM in cycle 1 might have 
received oral morphine at that time. If this patient continued using oral morphine during cycles 2 
and 3, the reported severity and distress could have been less. Because some patients might have 
received some form of pain medication, the reports are indicative of real life clinical experiences 
in which some patients may have been treated. Future research should begin in cycle 1 and 
control for and describe such interventions. 
In this secondary analysis, SM was used as a proxy for OM. The assumption was made that a 
patient receiving chemotherapy who had a complaint of a SM at least three times during a 
chemotherapy cycle was experiencing OM. However, some patients’ SM may have resulted from 
other causes, such as dental prostheses. Although this dataset had the advantage of providing 
daily reports from outpatients who are not readily observable, the ideal study would examine this 
issue using a prospective repeated-measures design that measured OM using a reliable and valid 
observational approach. 
Finally, because of the exploratory nature of VGA, there are limitations in its use. VGA can be a 
time-intensive procedure and is appropriate for a smaller sample size when resources are limited. 
In this study, although there was an adequate sample based on estimates of five per cell, some 
categories yielded cell sizes less than expected and the results cannot be considered definitive. 
However, this exploratory analysis indicates that trajectories of sore mouth do vary by 
individual, and differences in trajectory may be related to treatment regimen and/or type of 
cancer. These findings are important to consider in the design of future studies. 
Conclusions 
 
This secondary data analysis provides clinicians and researchers with a technique to visualize the 
trajectory of a symptom over time. It documents a highly variable pattern of SM in patients 
receiving chemotherapy. It is important to understand a patient’s unique response in order to 
develop an appropriate assessment and treatment strategy. While health care providers may have 
witnessed one or many of the patterns of SM in their clinical practice, until now, there has been a 
lack of actual descriptive research that documented these patterns. Better understanding of the 
multifaceted problem of SM will ultimately lead to improved interventions to both alleviate and 
lessen the debilitative effects of OM and allow for the support of patients throughout the entire 
course of OM, not just when their pain is so intense that they cannot eat or drink or tolerate 
further cancer therapy. The improved understanding of the complex symptom of mucositis will 
ultimately improve the overall patient experience and allow patients to receive the chemotherapy 
they need for a chance at long-term control and cure of their respective cancers. 
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